Atypical pathogen infection of respiratory system Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2021
DOI: https://doi.org/10.24292/01.MF.0121.10
Keywords:
Mycoplasma pneumoniae, Chlamydophila pneumoniae, atypical pneumonia, treatment, macrolides

Main Article Content

Adam J. Sybilski
1. II Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie. 2. Klinika Chorób Dziecięcych i Noworodkowych z Centrum Alergologii i Dermatologii, Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie

Abstract

The frequency of respiratory infections, especially atypical pneumonia, is increasing significantly. Most often, atypical pneumonia is caused by Mycoplasma pneumoniae and Chlamydophila pneumoniae. Human is the only reservoir of these atypical bacteria. The infection occurs via droplets or direct contact with a sick person or convalescent. Pneumonia of the etiology of Mycoplasma pneumoniae and Chlamydophila pneumoniae most often affects children without comorbidities and is usually mild, while most patients with Legionella infection require intensive care treatment. Symptoms of mycoplasma infection can range from mild symptoms in the upper respiratory tract to pneumonia and extrapulmonary symptoms. The infection is often underdiagnosed, and patients usually do not seek medical attention and treatment. Chlamydial pneumonia is, in most cases, mild, similar to Mycoplasma pneumoniae, and tends to heal itself. The drugs of choice in the treatment of atypical pneumonia are macrolides, and because of the best compliance in children – azithromycin.

Article Details

How to Cite
Sybilski, A. J. (2021). Atypical pathogen infection of respiratory system. Medycyna Faktow (J EBM), 14(1(50), 78-81. https://doi.org/10.24292/01.MF.0121.10
Issue
Vol 14 No 1(50) (2021)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Wiemken TL, Peyrani P, Ramirez JA. Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Care Med. 2012; 33(3): 213-9.
2. Yu Y, Fei A. Atypical pathogen infection in community-acquired pneumonia. BioScience Trends. 2016; 10(1): 7-13.
3. Canavan TN, Mathes EF, Frieden I et al. Mycoplasma pneumoniae induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: A systematic review. J Am Acad Dermatol. 2015; 72(2): 239-45.
4. Sharma L, Losier A, Tolbert T. Pneumonia Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia. Clin Chest Med. 2017; 38(1): 45-58.
5. Gong L, Zhang CL, Zhen Q. Analysis of clinical value of CT in the diagnosis of pediatric pneumonia and mycoplasma pneumonia. Exp Ther Med. 2016; 11(4): 1271-4.
6. Sztrymf B, Jacobs F, Fichet J et al. Mycoplasma-related pneumonia: a rare cause of acute respiratory distress syndrome (ARDS) and of potential antibiotic resistance. Rev Mal Respir. 2013; 30(1): 77-80.
7. Biscardi S, Lorrot M, Marc E et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis. 2004; 38(10): 1341-6.
8. Akashi Y, Hayashi D, Suzuki H et al. Clinical features and seasonal variations in the prevalence of macrolide-resistant Mycoplasma pneumoniae. J Gen Fam Med. 2018; 19(6): 191-7.
9. Yang TI, Chang TH, Lu CY et al. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? J Microbiol Immunol Infect. 2019; 52(2): 329-35.